Clinical Context Sleep deprivation has reached epidemic proportions in modern society, with many adults routinely sleeping less than the recommended 7-9 hours. While the metabolic consequences of sleep restriction—insulin resistance, weight gain, increased appetite—are increasingly recognized, effects on thyroid function are less well characterized. Given the thyroid axis’s central role in metabolism, energy expenditure, and cardiovascular health, understanding how sleep affects thyroid function has important public health implications. TSH secretion follows a circadian rhythm, with peak levels occurring during sleep. Sleep restriction could theoretically disrupt this pulsatile secretion, alter hypothalamic-pituitary-thyroid (HPT) axis set points, or affect peripheral thyroid hormone metabolism.…
Author: FWA
Summary: In healthy adult volunteers (Japanese n=20-21, non-Japanese n=20-21), single-dose cilofexor 100 mg or firsocostat 20 mg showed higher plasma exposure in Japanese participants: cilofexor AUCinf 1.24-fold higher, firsocostat AUCinf ~2-fold higher compared to non-Japanese participants, with both drugs well-tolerated in both populations, no dose adjustment required based on prior safety data. PICO Description Population Healthy adult volunteers: Japanese (n=20-21) and non-Japanese (n=20-21). Intervention Single-dose cilofexor 100 mg or firsocostat 20 mg with intensive PK sampling. Comparison PK parameters compared between Japanese and non-Japanese participants. Outcome Higher exposure in Japanese (1.24-2x). Well-tolerated. No dose adjustment needed. Clinical Context NASH drug…
Clinical Context Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease worldwide, affecting approximately 40% of patients with type 2 diabetes. Despite advances in glucose and blood pressure control, many patients progress to kidney failure requiring dialysis or transplantation. Until recently, SGLT2 inhibitors were the only glucose-lowering agents proven to slow DKD progression in dedicated renal outcomes trials. The FLOW trial (Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes) represents a watershed moment in nephrology: the first dedicated renal outcomes trial of a GLP-1 receptor agonist. While previous cardiovascular outcomes trials (SUSTAIN-6,…
Clinical Context Prediabetes affects approximately 96 million American adults—more than one-third of the adult population—and represents a critical window for diabetes prevention. Without intervention, 5-10% of individuals with prediabetes progress to type 2 diabetes annually, with up to 70% eventually developing the disease. Beyond diabetes risk, prediabetes itself is associated with increased cardiovascular disease, nephropathy, and neuropathy, making early intervention imperative. Landmark trials like the Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle intervention can reduce diabetes incidence by 58%, while metformin provides a more modest 31% reduction. However, sustaining lifestyle changes long-term remains challenging, and metformin’s effects are primarily…
Summary: In adults with obesity-related HFpEF (BMI ≥30) from pooled STEP-HFpEF trials (n=1,145), stratified by baseline diuretic use, once-weekly semaglutide 2.4 mg for 52 weeks produced consistent weight reduction (-6.9% to -8.8%), greater symptom improvement in loop diuretic users (+9.3 vs +4.7 KCCQ points), and reduced loop diuretic doses by 17% compared to placebo (which showed 2.4% diuretic dose increase), with no significant safety signals across diuretic subgroups. PICO Description Population Adults with obesity-related HFpEF (BMI ≥30), pooled STEP-HFpEF trials (n=1,145), stratified by diuretic use. Intervention Semaglutide 2.4 mg subcutaneously once weekly for 52 weeks plus standard HFpEF care. Comparison…
In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Summary: In healthy Chinese adults (n=32), once-daily oral semaglutide escalated from 3 mg to 14 mg over 12 weeks demonstrated dose-dependent exposure (AUC, Cmax) comparable to global populations, with significant reductions in body weight (P=0.0001) and fasting glucose (P=0.0011) compared to matching placebo, with primarily GI adverse events (nausea, decreased appetite), no severe hypoglycemia or serious AEs. PICO Description Population Healthy Chinese adults (n=32), randomized to oral semaglutide or placebo. Intervention Once-daily oral semaglutide with dose escalation 3 mg → 7 mg → 14 mg over 12 weeks. Comparison Matching placebo under identical conditions (fasting, 30-min post-dose fasting). Outcome Dose-dependent…
Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and certain cancers. Beyond physical health, obesity significantly impacts quality of life, physical functioning, and psychological wellbeing. Traditional weight management approaches combining diet and exercise typically achieve modest weight loss of 3-5%, often insufficient to meaningfully improve health outcomes or quality of life. The STEP (Semaglutide Treatment Effect in People with obesity) program represents the largest clinical trial program for anti-obesity pharmacotherapy to date. These Phase 3 trials evaluated semaglutide 2.4 mg—a GLP-1 receptor agonist administered…
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular events has proven challenging. Previous weight loss interventions—whether through lifestyle modification, bariatric surgery, or medications—have struggled to demonstrate reduced cardiovascular mortality in randomized trials. This evidentiary gap led some to question whether obesity itself causes cardiovascular events or merely travels alongside other risk factors. The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) fundamentally changed this landscape. It was the first dedicated cardiovascular outcomes trial of an anti-obesity medication in patients without diabetes, and it…